News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 198112

Sunday, 11/30/2014 1:59:14 AM

Sunday, November 30, 2014 1:59:14 AM

Post# of 347009

On these bases it is possible to speculate that the identification of molecular pathways involved in MDSC function will lead to the development of new tailored agents able to disrupt the tumor-host immunosuppressive interactions, thus improving the efficacy of both humoral and cellular immunotherapy.

We now predict a new era for immunotherapy in MM which will provide breakthrough improvements in the treatment of this important still incurable disease.



---------------------------

Looks like MDSC's are becoming rather important...as the above quote comes from the Nov 2014 Italian based research on MDSC's... below we have Millions going into UTSWM for new research re: MDSC's ...

---------------------------

CPRIT awards UTSW faculty $22.5 million for recruitment and research in liver cancer, leukemia, and immunotherapy

Nov 24, 2014


...
...
These cells are called myeloid-derived suppressor cells (MDSC) and prevent natural killing of cancer cells, said Dr. Cruz, Chief of Dermatology at the Dallas VA Medical Center, Director of the Contact Allergy Clinic at UT Southwestern and holder of the Paul R. Bergstresser, M.D., Chair in Dermatology.

http://www.utsouthwestern.edu/newsroom/news-releases/year-2014/nov/cprit-grants.html

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y